Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.
Peranzoni E, Ingangi V, Masetto E, Pinton L, Marigo I. Peranzoni E, et al. Among authors: ingangi v. Front Immunol. 2020 Jul 24;11:1590. doi: 10.3389/fimmu.2020.01590. eCollection 2020. Front Immunol. 2020. PMID: 32793228 Free PMC article. Review.
Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules.
Pinton L, Magri S, Masetto E, Vettore M, Schibuola I, Ingangi V, Marigo I, Matha K, Benoit JP, Della Puppa A, Bronte V, Lollo G, Mandruzzato S. Pinton L, et al. Among authors: ingangi v. J Nanobiotechnology. 2020 Feb 17;18(1):31. doi: 10.1186/s12951-020-00589-3. J Nanobiotechnology. 2020. PMID: 32066449 Free PMC article.
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages.
Marigo I, Trovato R, Hofer F, Ingangi V, Desantis G, Leone K, De Sanctis F, Ugel S, Canè S, Simonelli A, Lamolinara A, Iezzi M, Fassan M, Rugge M, Boschi F, Borile G, Eisenhaure T, Sarkizova S, Lieb D, Hacohen N, Azzolin L, Piccolo S, Lawlor R, Scarpa A, Carbognin L, Bria E, Bicciato S, Murray PJ, Bronte V. Marigo I, et al. Among authors: ingangi v. Cancer Discov. 2020 Nov;10(11):1758-1773. doi: 10.1158/2159-8290.CD-20-0036. Epub 2020 Jul 10. Cancer Discov. 2020. PMID: 32651166
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
Nanda VGY, Peng W, Hwu P, Davies MA, Ciliberto G, Fattore L, Malpicci D, Aurisicchio L, Ascierto PA, Croce CM, Mancini R, Spranger S, Gajewski TF, Wang Y, Ferrone S, Vanpouille-Box C, Wennerberg E, Pilones KA, Formenti SC, Demaria S, Tang H, Wang Y, Fu YX, Dummer R, Puzanov I, Tarhini A, Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sanders C, Kirkwood JM, Chen THT, Maurer M, Korman AJ, Zarour HM, Stroncek DF, Huber V, Rivoltini L, Thurin M, Rau T, Lugli A, Pagès F, Camarero J, Sancho A, Jommi C, de Coaña YP, Wolodarski M, Yoshimoto Y, Gentilcore G, Poschke I, Masucci GV, Hansson J, Kiessling R, Scognamiglio G, Sabbatino F, Marino FZ, Anniciello AM, Cantile M, Cerrone M, Scala S, D’alterio C, Ianaro A, Cirin G, Liguori G, Bott G, Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Testori A, Lorigan P, Sosman JA, Flaherty KT, Yue H, Coleman S, Caro I, Hauschild A, McArthur GA, Sznol M, Callahan MK, Kluger H, Postow MA, Gordan R, Segal NH, Rizvi NA, Lesokhin A, Atkins MB, Burke MM, Ralabate A, Rivera A, Kronenberg SA, Agunwamba B, Ruisi M, Horak C, Jiang J, Wolchok J, Ascierto PA, Liszkay G, Maio M, Mandalà M, Demidov L, Stoyakovskiy D, Thomas L, de la Cruz-Me… See abstract for full author list ➔ Nanda VGY, et al. Among authors: ingangi v. J Transl Med. 2016 Jul 25;14(1):65. doi: 10.1186/s12967-016-0791-2. J Transl Med. 2016. PMID: 27461275 Free PMC article.
Gangadhar O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H. …
Gangadhar O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectabl …
Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Ragone C, Minopoli M, Ingangi V, Botti G, Fratangelo F, Pessi A, Stoppelli MP, Ascierto PA, Ciliberto G, Motti ML, Carriero MV. Ragone C, et al. Among authors: ingangi v. J Exp Clin Cancer Res. 2017 Dec 8;36(1):180. doi: 10.1186/s13046-017-0650-x. J Exp Clin Cancer Res. 2017. PMID: 29216889 Free PMC article.
Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.
Carriero MV, Bifulco K, Ingangi V, Costantini S, Botti G, Ragone C, Minopoli M, Motti ML, Rea D, Scognamiglio G, Botti G, Arra C, Ciliberto G, Pessi A. Carriero MV, et al. Among authors: ingangi v. Sci Rep. 2017 May 2;7(1):1312. doi: 10.1038/s41598-017-01425-9. Sci Rep. 2017. PMID: 28465589 Free PMC article.
16 results